DHR · News · 20261022N

Guidance / Outlook

DANAHER CORP /DE/ · 2026-10-22 · Importance 51 · Surprise 60 · In source text

Management slightly raised its full-year 2026 adjusted EPS guidance to a midpoint of $8.59. Analysts expected more than 5% organic growth, particularly from Cytiva, but identified respiratory revenue pressure as a forward-looking challenge. Analysts also described the 2027 outlook as conservative. The outlook discussion emphasized improved execution, innovation, and capital-allocation discipline under new CEO Julie Sawyer Montgomery.

Key facts

• Management slightly raised full-year Adjusted EPS guidance to $8.59 at the midpoint source
• Stifel raised its Danaher price target to $260 from $220 and cited an expectation of more than 5% organic growth driven by Cytiva source
• JP Morgan raised its target price for Danaher shares to $270 from $250 source
• Analysts' price targets were described in one article as edging into the US$240 to US$255 range with some models centering around fair value of about US$244.14 source
• UBS reiterated a Buy rating on Danaher with a $260.00 price target following the company's Q3 results source

Impact estimates